



OPEN ACCESS

EDITED BY

Stefan Brocke,
University of Connecticut Health Center,
United States

REVIEWED BY

Paul Mark Epstein,
UCONN Health, United States
Robert B. Nelson,
MindImmune Therapeutics, Inc.,
United States

*CORRESPONDENCE

Peter Nickolaus,
✉ peter.nickolaus@boehringer-
ingelheim.com

RECEIVED 09 May 2023

ACCEPTED 22 May 2023

PUBLISHED 30 May 2023

CITATION

Herrmann FE, Hesslinger C, Wollin L and
Nickolaus P (2023), Corrigendum: BI
1015550 is a PDE4B inhibitor and a clinical
drug candidate for the oral treatment of
idiopathic pulmonary fibrosis.
Front. Pharmacol. 14:1219760.
doi: 10.3389/fphar.2023.1219760

COPYRIGHT

© 2023 Herrmann, Hesslinger, Wollin and
Nickolaus. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original author(s)
and the copyright owner(s) are credited
and that the original publication in this
journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis

Franziska Elena Herrmann, Christian Hesslinger, Lutz Wollin and
Peter Nickolaus*

Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany

KEYWORDS

PDE4B, IPF, lung fibrosis, phosphodiesterase, cAMP, ILDs

A Corrigendum on

[BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis](#)

by Herrmann FE, Hesslinger C, Wollin L and Nickolaus P (2022). *Front. Pharmacol.* 13:838449. doi: 10.3389/fphar.2022.838449

In the original article, there was an error in [Table 1](#) as published. The *n* numbers given in the legend to [Table 1](#) were only applicable to the first row of the table. The corrected [Table 1](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

TABLE 1 Inhibition of human recombinant PDE4 subtypes by BI 1015550 in comparison to roflumilast and its active metabolite Roflu-N-Ox. IC₅₀ values (nmol/L) are given as means from *n* independent experiments. Cell extracts containing the active site fragments mediated the conversion of 10 μL [³H]cAMP (0.05 μCi in H₂O) to AMP resulting in the binding of this radiolabeled molecule to the yttrium silicate SPA beads and the subsequent generation of scintillation events determined using a Wallac Microbeta counter. AMP, adenosine monophosphate; IC₅₀, inhibitory concentration (nM) for half-maximal inhibition; PDE, phosphodiesterase; SPA, scintillation proximity assay.

	PDE4A	PDE4B2	PDE4C2	PDE4D2
BI 1015550	248 (<i>n</i> = 3)	10 (<i>n</i> = 2)	8,700 (<i>n</i> = 3)	91 (<i>n</i> = 2)
Roflumilast	1.4 (<i>n</i> = 2)	0.6 (<i>n</i> = 12)	12 (<i>n</i> = 2)	0.8 (<i>n</i> = 12)
Roflu-N-Ox	2.8 (<i>n</i> = 1)	1.4 (<i>n</i> = 6)	15 (<i>n</i> = 1)	1.4 (<i>n</i> = 6)

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.